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Based on recent evidence that fatty acid synthase and endog-
enously produced fatty acid derivatives are required for adipo-
genesis in 3T3-L1 adipocytes, we conducted a small interfering
RNA-based screen to identify other fatty acid-metabolizing
enzymes that may mediate this effect. Of 24 enzymes screened,
stearoyl-CoA desaturase 2 (SCD2) was found to be uniquely and
absolutely required for adipogenesis. Remarkably, SCD2 also
controls the maintenance of adipocyte-specific gene expression
in fully differentiated 3T3-L1 adipocytes, including the expres-
sion of SCD1. Despite the high sequence similarity between
SCD2 and SCD1, silencing of SCD1 did not down-regulate
3T3-L1 cell differentiation or gene expression. SCD2 mRNA
expression was also uniquely elevated 44-fold in adipose tissue
upon feeding mice a high fat diet, whereas SCD1 showed little
response. The inhibition of adipogenesis caused by SCD2deple-
tion was associated with a decrease in peroxisome proliferator-
activated receptor  (PPAR) mRNA and protein, whereas in
mature adipocytes loss of SCD2 diminished PPAR protein lev-
els, with little change in mRNA levels. In the latter case, SCD2
depletion did not change the degradation rate of PPARprotein
but decreased the metabolic labeling of PPAR protein using
[35S]methionine/cysteine, indicating protein translation was
decreased. This requirement of SCD2 for optimal protein syn-
thesis in fully differentiated adipocyteswas verified by polysome
profile analysis, where a shift in the mRNA to monosomes was
apparent in response to SCD2 silencing. These results reveal
that SCD2 is required for the induction and maintenance of
PPAR protein levels and adipogenesis in 3T3-L1 cells.
The ability of adipocytes to sense and respond to circulating
fatty acid levels is important in maintaining the proper balance
between fatty acid storage and fatty acid release for energy uti-
lization. In the case of energy excess, fatty acids are stored in the
form of triglyceride, and new adipocytes are generated to effi-
ciently metabolize amino acids, glucose, and fatty acids to trig-
lyceride (1). The key regulator of adipogenesis, the process
whereby preadipocytes differentiate into fully mature adipo-
cytes, is the ligand-activated nuclear receptor PPAR2 (2). Cul-
tured mouse 3T3-L1 preadipocytes are an excellent model sys-
tem for the study of adipogenesis. These cells differentiate into
adipocytes withmultilocular lipid droplets through a transcrip-
tional cascade beginning with the rapid and transient expres-
sion of C/EBP and C/EBP (3, 4). The up-regulation of these
transcription factors precedes the expression of PPAR and
C/EBP, which are critical for the completion of adipogenesis
as well as the maintenance of adipocyte-specific gene expres-
sion in fully differentiated cells (3, 4). Other transcription fac-
tors have also been shown to play significant roles in adipogen-
esis and adipocyte biology (for reviews, see Refs. 3, 5, and 6).
However, because PPAR controls the expression of large sets
of genes required to maintain the adipocyte phenotype, includ-
ing C/EBP itself, a loss in the activity or expression of PPAR
leads to a loss in adipocyte function (7).
Although it is unclear whether ligands actively modulate
PPAR activity in fully differentiated adipocytes, ligand-medi-
ated activation of PPAR appears to be required for transcrip-
tional activity during adipogenesis (8). Because PPAR has a
large hydrophobic ligand binding domain (9) and activation
occurs in response to fatty acids (10), endogenous long chain
fatty acids or their derivatives have been proposed as natural
ligands. These include oleate, linoleate, nitrolinoleate, nitro-
oleate, 9-hydroxydecaenoic acid, arachidonic acid, and 15-de-
oxy-prostaglandin J2 (11–15). Despite the many proposed
ligands, nitrolinoleate and nitro-oleate are the only fatty acids
with a high binding affinity, but it has not yet been verified that
these fatty acids are truly endogenous PPAR ligands in adipo-
cytes (13, 15). Because several low affinity fatty acid ligands
activate PPAR (11–13, 16, 17), this nuclear receptor may
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instead serve as a general fatty acid sensor, allowing proper
expression of fatty acid metabolizing enzymes and the genera-
tion of new adipocytes.
In addition, it appears that differentiating adipocytes can
fully synthesize a PPAR ligand, since preadipocytes will differ-
entiate and produce a PPAR ligand in the absence of exoge-
nous fatty acids (14, 18). Furthermore, overexpression of sterol
regulatory element-binding protein-1 (SREBP1) in adipocytes
apparently increases ligand production (19), whereas inhibition
of acetyl-CoA carboxylase (ACC) (20) or fatty acid synthase
(FAS) (21) inhibits adipogenesis. SREBP1 is a transcription fac-
tor that controls the expression ofmany fatty acidmetabolizing
enzymes, including ACC and FAS. Because ACC and FASwork
sequentially to produce palmitate, it is possible that sterol reg-
ulatory element-binding protein-1 promotes PPAR ligand
production through a pathway involving ACC and FAS.
Although there may be several explanations for the require-
ment of SREBP1, ACC, or FAS for adipogenesis apart from
PPAR ligand production, these studies do support the notion
that endogenously synthesized fatty acids are required for
adipogenesis.
Because adipocytes express multiple fatty acid-metabolizing
enzymes, these cells apparently produce highly diverse lipid
species that may affect cellular signaling events, including
PPAR activation. Thus, the aim of the present study was to
identify enzymes involved in fatty acid synthesis or metabolism
that may mediate such signaling pathways through their fatty
acid products. To achieve this goal, we set up a screen in which
24 fatty acid-metabolizing enzymes were individually depleted
using siRNA oligonucleotides to identify enzymes that are
required for adipocyte-specific gene expression. Through this
siRNA screen, we identified the fatty acid9-desaturase, stear-
oyl-CoA desaturase 2 (SCD2), as a required enzyme for 3T3-L1
cell adipogenesis and for themaintenance of adipocyte-specific
gene expression in fully differentiated cells. Importantly, SCD2
was found to be required for PPAR induction during differen-
tiation of 3T3-L1 cells and for PPAR expression in fully differ-
entiated adipocytes. Related to this latter effect, SCD2 expres-
sion was found to promote protein translation, secondarily
affecting PPAR protein levels. Surprisingly, although SCD1
and SCD2 exhibit high sequence similarity, are both expressed
in the endoplasmic reticulum of the adipocyte, and are pre-
dicted to produce the same products, SCD1 depletion failed to
attenuate PPAR expression or adipogenesis. Therefore, these
results identify SCD2 as a key regulator of adipocyte function by
promoting PPAR protein synthesis and reveal a novel and spe-
cific role for SCD2 versus SCD1 in the adipocyte.
EXPERIMENTAL PROCEDURES
Animals—All procedureswere carried out following theUni-
versity of Massachusetts Medical School Institution Animal
Care and Use Committee guidelines. Four-week-old male
C57BL/6J mice were purchased from The Jackson Laboratory
(Bar Harbor, ME) and maintained in a 12-h light/dark cycle.
Half of the mice were fed a standard mouse chow (10% kcal of
fat), and the other half was fed a high fat diet (55% kcal of fat) ad
libitum for 18 weeks. The animals were fasted for 18 h before
harvesting the tissues. Animals were sacrificed, epididymal fat
pads were harvested from the mice and placed in KRH buffer
(pH 7.4) supplemented with 2.5% bovine serum albumin, and
RNA was collected using TRIzol (Invitrogen) for subsequent
Affymetrix GeneChip analysis.
Materials—Rosiglitazone was purchased from Biomol
(Plymouth Meeting, PA). The proteasome inhibitor, MG132,
was purchased from Calbiochem. Mouse monoclonal anti-
PPAR, mouse monoclonal anti-AKT1, mouse monoclonal
anti- catenin, rabbit polyclonal anti-PPAR, and rabbit poly-
clonal anti-C/EBP antibodies were purchased from Santa
Cruz Biotechnology. Rabbit anti-AMP-activated protein
kinase, eEF2, RS6K, and eIF2 were purchased from Cell Sig-
naling (Danvers, MA). Protein A-Sepharose beads were pur-
chased from Sigma. Rabbit PTEN antiserum was purchased
from Upstate Biotechnology (Charlottesville, VA). The MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) cell proliferation assay kit and
TdT-mediated dUTP nick-end labeling kit were purchased
from Promega (Madison, WI). The iScript cDNA synthesis
kit and the iQ SYBR green supermix kit were purchased from
Bio-Rad. [35S]Methionine/cysteine was purchased from
PerkinElmer Life Sciences.
siRNA Duplexes—The siRNA purchased from Dharmacon
Inc.(Lafayette, CO)were designed to target the following cDNA
sequences: scrambled, 5-CAGTCGCGTTTGCGACTGG-3;
SCD2, 5-GAGCAGATGTTCGCCCTGATT-3; PPAR, 5-
GACATGAATTCCTTAATGA-3; SCD1, 5-GCCTAGAAC-
TGATAACTAATT-3. Proprietary SMART-pool siRNA
duplexes were used to target all other transcripts.
Cell Culture and Electroporation—3T3-L1 fibroblasts were
cultured inDulbecco’smodified Eagle’smedium supplemented
with 10% fetal bovine serum, 50 g/ml streptomycin, and 50
units/ml penicillin (22). For experiments performed during dif-
ferentiation, fibroblasts were cultured for 7 days, and 5  106
cells were electroporated with 20 nmol of siRNA. The electro-
poration was performed using a Bio-Rad Gene Pulser II at the
setting of 0.18 kV and 960 microfarads. Immediately after elec-
troporation, the cells were reseeded into 2 wells of a 6-well
plate. After 24 h, differentiation media consisting of 2.5 g/ml
insulin, 0.25 M dexamethasone, and 0.5 mM 3-isobutyl-1-
methyl-xanthine in the culture media described above was
added for 72 h in the absence or presence of 1M rosiglitazone.
After 72 h, differentiation media was replaced with culture
media for an additional 24 h, and then RNA or protein was
collected. For experiments in mature adipocytes, fibroblasts
were cultured for 8 days, differentiated into mature adipocytes
as described above, and cultured for an additional 7 days. Adi-
pocytes were then electroporated (20 nmol of siRNA/5  106
cells) as described above. After electroporation, cells were
reseeded into multiple-well plates, and RNA or protein was
collected 4–72 h post-electroporation.
Affymetrix Gene Chip Analysis—Total RNA was collected
from day 10 adipocytes after 72 h of siRNA treatment or from
preadipocyte fibroblasts, adipocytes, and primary fat tissue as
described (23). Subsequent reactions were carried out as
already described (24). Only signals considered present were
used for further analysis. Ifmore than one probe is present, only
one representative probe is shown.
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RNA Isolation and Real Time-PCR—Total RNA was col-
lected using TRIzol (Invitrogen), and reverse transcription and
real time-PCR analysis were carried out as already described
(24, 50). Primers were chosen from the PrimerBank online data
base (25). AKT1 was used as the internal control.
Immunoblotting—Cells were solubilized with lysis buffer
containing 25 mM Hepes (pH 7.5), 0.5% Nonidet P-40, 1 mM
EGTA, 1mM EDTA, 1% SDS, 12.5mMNaF, 5mM sodium pyro-
phosphate, 5 mM -glycerophosphate, 5 mM sodium vanadate,
1 mM phenylmethylsulfonyl fluoride, 5g/ml aprotinin, and 10
g/ml leupeptin. Protein was quantified using the BCA protein
assay kit (Pierce) and then resolved on a 8% SDS-PAGE gel,
electrotransferred to nitrocellulose, blocked with 5% bovine
serumalbumin and 5%nonfatmilk inTBST (0.05%Tween 20 in
Tris-buffered saline), washed with TBST, and incubated with
specific antibody at 4 °C overnight. The blots were then washed
with TBST, and a horseradish peroxidase anti-mouse or anti-
rabbit secondary antibodywas applied. Proteinswere visualized
using an enhanced chemiluminescent substrate kit (Amersham
Biosciences), and immunoblot band intensities were quantified
by scanning densitometry using Photoshop.
Oil Red O Staining—Cells were fixed with 4% formaldehyde
for 1 h at room temperature, washed 3 times with PBS, perme-
abilized with P-buffer (0.5% Triton X-100, 1% fetal bovine
serum, and 0.05% sodium azide) for 20 min, incubated with Oil
RedO solution (5mg/ml Oil RedO solid dissolved in isopropa-
nol then diluted to a 60%working solutionwith double-distilled
H20) for 30 min, washed 3 times with distilled water, and ana-
lyzed by light microscopy or visual inspection.
[35S]Methionine/Cysteine Labeling and Immunoprecipita-
tion of PPAR—Seventy-two hours after electroporation of
cells with siRNA, one 100-mm plate of cells was starved of
methionine and cysteine for 2 h and then labeled with 500 Ci
of [35S]methionine/cysteine for 4 h. Cells were then lysed in
ice-cold buffer containing 25mMHepes (pH 7.5), 0.5%Nonidet
P-40, 1 mM EGTA, 1 mM EDTA, 1% SDS, 12.5 mM NaF, 5 mM
sodium pyrophosphate, 5 mM -glycerophosphate, 5 mM
sodiumvanadate, 1mMphenylmethylsulfonyl fluoride, 5g/ml
aprotinin, and 10 g/ml leupeptin. Total cell lysates of 1 mg of
protein were immunoprecipitated overnight with 20 g of
mouse monoclonal antibody against PPAR followed by incu-
bation with 50 l of protein A-Sepharose beads for 2 h at 4 °C.
The beads were then washed 5 times with lysis buffer before
boiling for 5min in Laemmli buffer. Protein was then separated
on an 8% SDS gel, transferred to nitrocellulose, and exposed to
a phosphor screen for 60 h. The screenwas then visualized with
a PhosphorImager (Molecular Dynamics). The nitrocellulose
was then immunoblotted as described above using goat poly-
clonal antibody against PPAR to detect the efficiency of the
immunoprecipitation.
Polysome Profile and Reverse Transcription-PCR—Polysome
profiles were generated as described previously (26–28).
Briefly, after siRNA transfection, cells were reseeded into one
10-cm dish. After 24 or 72 h, cycloheximide (Sigma) was added
at a final concentration of 100 mg/ml for 10 min. Cells were
then washed with PBS, trypsinized, pelleted, and resuspended
in polysome buffer (20 mM Tris-HCl (pH 7.5), 10 mM NaCl, 3
mM MgCl2) containing 150 g/ml cycloheximide and 100
units/ml RNasin (Promega). After determining the cell number
in each sample, Triton X-100 was added to the cell suspension
at a final concentration of 0.3% (v/v), and cells were passed
through a 27-gauge needle 5 times to ensure lysis. The nuclei
were then pelleted by centrifugation at 4 °C and 12,000 g for
5 min. The supernatant was then layered on a linear 10–50%
sucrose gradient in polysome buffer containing 10g/ml cyclo-
heximide and 3.3 units/ml RNasin, and the gradients were cen-
trifuged in a Beckmann SW41Ti Rotor at 141,000 g at 4 °C for
4 h. The gradientswere fractionated into 1-ml fractions, and the
UV absorption at A254 was recorded. Twelve fractions were
collected, andRNAwas then extracted fromeach fraction using
TRIzol (Invitrogen). Equal volumes of each fraction were then
reverse-transcribed, and real time PCR was performed as
already described (24).
RESULTS
Expression of Fatty Acid Metabolizing Enzymes in Cultured
Adipocytes andPrimaryAdiposeTissue—Toestablish a siRNA-
based screen of broad scope, we first identified key enzymes in
the major pathways of fatty acid metabolism that are clearly
expressed in both mouse 3T3-L1 adipocytes and primary
mouse adipose tissue. Fig. 1 illustrates eight pathways of fatty
acid metabolism that were considered for our studies, which
include -oxidation, -oxidation, -oxidation, elongation,
desaturation, nitration, epoxygenation/hydroxylation, and
isomerization. Identification of the enzymes shown in Fig. 1was
accomplished by Affymetrix GeneChip microarray analysis of
samples obtained from 3T3-L1 preadipocytes versus 3T3-L1
adipocytes (6 days after initiation of differentiation) and from
the adipose tissue ofmice fed a normal diet versus a high fat diet
for 16 weeks. Table 1 presents the list of specific genes we
selected by this analysis, all of which were found to be signifi-
cantly expressed in both model systems. Boldface shows values
FIGURE 1.Diagram showing themultiple pathways of fatty acidmetabo-
lism inadipocytes.Asaturated fatty acidmaybe-oxidized, formingadicar-
boxylic acid; -oxidized, cleaving two carbons per cycle from the fatty acid;
-oxidized, cleaving one carbon per cycle from the fatty acid; Elongated, add-
ing two carbons per cycle to the fatty acid;Desaturated, forming a cis-double
bond between the 9 and 10, 5 and 6, 6 and 7, or possibly the 4 and 5 carbons.
The double bond in a desaturated fatty acid may then change position
through isomerases or be nitrated or oxidized, producing various side groups
on the fatty acid (seeunder “Results” for further details). EPHX, epoxidehydro-
lase; ACOX, acyl-CoA oxidase.
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for -fold change in expression for genes that are significantly
up-regulated or down-regulated in response to 3T3-L1 differ-
entiation (Table 1). The values obtained for SCD1 and SCD2
are highlighted within the rectangle.
The fatty acid-metabolizing enzymes shown in Table 1 and
Fig. 1 allow the generation ofmany different fatty acid products
and derivatives from the same initial fatty acid substrate. A
saturated fatty acid such as palmitate may be 1) -oxidized by
the cytochrome P450 enzyme CYP4f16, forming a dicarboxylic
acid, 2) -oxidized in peroxisomes by the acyl-CoA oxidases
ACOX1 and ACOX2 or in the mitochondria by the acyl-CoA
dehydrogenasesACADl andACADvl, cleaving two carbons per
cycle from the fatty acid, 3) -oxidized in peroxisomes by
phytanoyl-CoA hydroxylase, cleaving one carbon per cycle
from the fatty acid, 4) elongated by ELOVL1, ELOVL3,
ELOVL5, and ELOVL6, which are present in the endoplasmic
reticulum, adding two carbons per cycle to the fatty acid, or 5)
desaturated by various enzymes found in the endoplasmic
reticulum, including stearoyl-CoA desaturase 1 or stearoyl-
CoA desaturase 2, forming a cis double bond between the 9 and
10 carbons, or fatty acid desaturase 1, fatty acid desaturase 2, or
fatty acid desaturase 3, forming a cis double bond between 5
and 6, 6 and 7, and possibly the 4 and 5 carbons, respectively. In
addition, the double bond in an unsaturated fatty acid may
change position through the isomerase, ALOXe3, found in the
cytoplasm, be nitrated by nitric oxide species produced by
nitric-oxide synthase, found in the cytoplasm, or be oxidized by
the cytochrome P450 enzymes CYP2f2, CYP2c55, CYP20a1,
CYP26b1, CYP1b1, found in the endoplasmic reticulum, add-
ing an epoxide, hydroxyl, or peroxyl group to the fatty acid. An
epoxidemay then be furthermetabolized by the epoxide hydro-
lase, EPHX1, present in the endoplasmic reticulum, or EPHX2,
present in the cytoplasm, producing dihydrodiols. Additionally,
these pathways can operate in tandem, changing the carbon
length or position of a side group or double bond within the
fatty acid. Because a fatty acid produced from any one of these
pathways may affect cell signaling events or other processes,
these enzymes listed in Table 1 were targeted in a siRNA-based
screen to determine whether they affect adipocyte gene expres-
sion in 3T3-L1 cells.
SCD2, but Not SCD1, Is Required for 3T3-L1 Adipogenesis—
To identify fatty acid metabolizing enzymes that are
required for 3T3-L1 adipogenesis, siRNA oligonucleotides
directed against each of the enzymes identified by the
microarray analysis in Table 1 were electroporated into
3T3-L1 preadipocytes before differentiation. Because
PPAR appears to be activated by an endogenous ligand dur-
ing adipogenesis (8, 11–13, 16), we reasoned that if a
depleted enzyme is required specifically for the production
of a PPAR ligand, the addition of an exogenous ligand may
reverse the effect of such enzyme depletion. Thus, in our
screen the enzymes were also depleted in the presence of the
PPAR specific ligand, rosiglitazone, as a control. The initial
screen monitored the mRNA transcript levels by real time
PCR of the differentiation-induced proteins PPAR and
GLUT4 (Fig. 2). As expected, the well established required
factors for adipocyte differentiation, PPAR and FAS (21),
did indeed attenuate PPAR and GLUT4 expression in this
screen when depleted by siRNA and acted as positive con-
trols. In addition, rosiglitazone treatment did not restore
PPAR or GLUT4 levels upon siRNA-based depletion of
PPAR (Fig. 2 and supplemental Fig. 1). Importantly, of the
remaining 24 enzymes screened, only SCD2 depletion
potently inhibited gene expression during adipogenesis (Fig.
2, A and B).
Interestingly, despite the predicted similarity in substrate
selectivity between SCD1 and SCD2 (29), depletion of SCD1 in
3T3-L1 cells did not inhibit PPAR orGLUT4 expression (Figs.
2 and supplemental Fig. 1). Furthermore, the addition of ros-
iglitazone did not restore the transcript levels of PPAR or
GLUT4 upon loss of SCD2 or FAS (Fig. 2 and supplemental Fig.
1). This suggests that if SCD2 and FAS are involved in PPAR
ligand production during adipogenesis, the enzymes are also
required for an independent function.
In an attempt to confirm and extend these findings, expres-
sion of PPAR protein was measured in a second screen of 10
enzymes, again revealing that SCD2, but not SCD1, is abso-
TABLE 1
Affymetrix Gene Chip analysis of fatty acid metabolizing enzymes in
differentiating 3T3-L1 adipocytes and primary adipocytes frommice
fed a normal chow or high fat diet
RNA was collected from 3T3-L1 cells before differentiation or 2, 4, and 6 days
post-differentiation and subjected to Affymetrix Gene Chip analysis. RNA from
three different samples was collected and pooled and then analyzed on one array;
each experiment was done in triplicate, resulting in a total of nine RNA samples and
three arrays for each timepoint. Fromtheprimary adipocytes,RNAwascollected from
23 mice fed a normal chow diet and 14 mice fed a high fat diet for 18 weeks. The mice
were divided into three groups within each diet condition, and the RNA from each
groupwas pooled and then analyzed on one array, resulting in three arrays for each diet
condition. Shown are representative values for the -fold changes in gene expression
during adipogenesis or due to high fat diet. Boldface shows values that are significantly
up-regulated or down-regulated in response to 3T3-L1 differentiation. The values
obtained for SCD1 and SCD2 are in the rectangle. The asterisk denotes a p value0.05.
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lutely required for expression of this transcription factor (Fig.
3A). In addition, when preadipocytes differentiate into adipo-
cytes, the cells become smaller and rounder, losing their fibro-
blastic morphology. The cells also acquire the ability to accu-
mulate lipid in the form of triglyceride, appearing as lipid
droplets in the cytoplasm (3, 14). Oil RedO staining of accumu-
lated neutral lipids in cells 4 days after the initiation of differ-
entiation confirms that PPAR and SCD2 are required for the
lipid accumulation (Fig. 3B) and morphological changes (data
not shown) that occur during adipogenesis, whereas SCD1 is
not. Therefore, SCD2, but not SCD1, is required for several
aspects of adipogenesis, including the induction of adipocyte
specific genes, the increase in lipid accumulation, and the gain
in the adipocyte morphology.
To verify that the inhibition of adipogenesis by depletion of
PPAR, FAS, or SCD2 is not due to general toxicity, metabolic
activity was measured in the cells using the tetrazolium com-
pound,MTS.MTS is reduced by the cells to a colored formazan
product, presumably by NADPH or NADH produced by dehy-
drogenase enzymes, and therefore, is an indirect measure of
dehydrogenase activity. As seen in Fig. 4A, depletion of the
various enzymes using siRNA did not cause a reduction in
dehydrogenase activity, and therefore, the inhibition of adipo-
genesis does not appear to be due to general toxicity. We also
found an increase in the expression of several caspases with
SCD2 depletion (supplemental Table 1). Because caspases are
involved in apoptosis, a TdT-mediated dUTP nick-end labeling
assay was performed to ensure that the siRNA treatment does
not induce apoptosis. This assay utilizes fluorescein-12-
dUTP and terminal deoxynucleotidyltransferase to fluores-
cently label the fragmented DNA of apoptotic cells on the
free 3OH DNA ends. The fluorescence of the cell popula-
tion is then quantitated by flow cytometry to determine the
extent of apoptosis occurring within the cell population. As
can be seen in Fig. 4B, depletion of PPAR, FAS, SCD1, or
SCD2 does not induce apoptosis, and therefore, the affects
on gene expression are not due to this toxic event.
SCD2, but Not SCD1, Is Required for Adipocyte-specific Gene
Expression in Fully Differentiated Adipocytes—Real time PCR
analysis reveals that SCD2 expression is higher in preadipocyte
fibroblasts than SCD1 expression (supplemental Fig. 2, A and
C), but 6 days after the induction of differentiation, SCD1
expression increases by 23-fold (supplemental Fig. 2B), whereas
SCD2 expression only increases by8-fold (supplemental Fig.
A. PPARγ mRNA levels in cells treated with siRNA 
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FIGURE 2.Depletionof SCD2 inhibits themRNAexpressionof adipogenic
markers in differentiating 3T3-L1 adipocytes. Confluent fibroblasts were
electroporated with scrambled nucleotide as a control or SMART-pool siRNA
directed against various fatty acid metabolizing enzymes and reseeded in
duplicatewells as described under “Experimental Procedures”. After 24 h, the
cells were differentiated in the presence or absence of 1M rosiglitazone. On
the fourth day of differentiation, RNAwas collected to determine the expres-
sion of PPAR (A), GLUT4 (B), or SCD1 and SCD2 (C) by real time PCR using
AKT1 as an internal control. The results shown in A and B were performed
once as part of the initial screen; the results shown inC are an averageof three
independent experiments, and the asterisk denotes a p value 0.01. EPHX,
epoxide hydrolase; ACOX, acyl-CoA oxidase; NOS, nitric-oxide synthase.
FIGURE 3.Depletion of SCD2 inhibits adipogenic protein expression and
morphological changes in differentiating 3T3-L1 adipocytes. Confluent
fibroblasts were electroporated with scrambled nucleotide as a control or
SMART-pool siRNA directed against various fatty acid metabolizing enzymes
and reseeded in duplicate wells as described under “Experimental Proce-
dures.” After 24 h the cells were differentiated in the presence or absence of 1
M rosiglitazone. On the fourth day of differentiationproteinwas collected to
determine the expression of PPAR by Western blot using PTEN as a loading
control; densitometry values reflect the ratio of PPAR to PTEN (A). B, cells
were electroporated and differentiated as described in A, then fixed and
stained with Oil Red O 4 days post-differentiation. ACOX, acyl-CoA oxidase.
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2,B andC). This dramatic induction of SCD1 expression results
in higher SCD1 than SCD2 expression in fully differentiated
cells (supplemental Fig. 2, A and C). Because SCD2 depletion
inhibits the increase in SCD1 expression during adipogenesis
(Fig. 2C), perhaps the inhibition of adipogenesis is not due
solely to SCD2 depletion but is dependent on a decrease in total
desaturase activity. Therefore, perhaps the more profound
effect of SCD2 depletion on adipogenesis is simply due to its
higher expression in the preadipocyte. We, therefore, tested
whether SCD1 or SCD2 are required to sustain adipocyte-spe-
cific gene expression in fully differentiated adipocytes (7 days
after initiation of differentiation), when SCD1 expression is
dramatically higher than SCD2 expression (supplemental Fig.
2C). Remarkably, real time-PCR analysis of the products of sev-
eral adipocyte genes revealed that SCD2, but not SCD1, is nec-
essary for optimal expression of the PPAR-regulated genes,
phosphoenolpyruvate carboxy kinase, andACC in fully differ-
entiated cells (Fig. 5A). However, SCD2 knockdown in these
fully differentiated adipocytes only caused a minor decrease in
PPARmRNA expression (Fig. 5A), in contrast to SCD2 deple-
tion in cells before differentiation (Fig. 2A). Therefore, the
expression of PPAR1 and PPAR2 protein was determined by
Western blot (Fig. 5B). Surprisingly, the protein levels of both
PPAR isoforms were markedly decreased in fully differenti-
ated adipocytes upon siRNA-mediated depletion of SCD2 and
not affected by depletion of SCD1. FAS is also required for
phosphoenolpyruvate carboxy kinase and ACC expression in
fully differentiated cells, but this effect is not due to a decrease
in PPAR expression, since FAS depletion did not cause a sig-
nificant decrease in PPARmRNA or protein expression (Figs.
5, A and B). Thus, the maintenance of PPAR protein in fully
differentiated cultured adipocytes is specifically dependent on
SCD2 activity, explaining the requirement of SCD2 for phos-
phoenolpyruvate carboxy kinase and ACC gene expression.
To compare the sets of adipocyte genes regulated by SCD2
depletion versus PPAR depletion, Affymetrix Gene Chip anal-
ysis was performed in fully differentiated adipocytes electropo-
rated with siRNA directed against PPAR, SCD1, or SCD2. Fig.
6 illustrates the results of this analysis as a heatmap showing the
comparison of genes that change in expression with the differ-
ent siRNA treatments. The green bars represent genes that are
significantly up-regulated, and the red bars represent genes that
are significantly down-regulated in the cells treatedwith siRNA
versus scrambled nucleotide control. Not surprisingly, SCD2
depletion has a profound effect on gene expression that
strongly parallels the effects of PPAR depletion, whereas loss
of SCD1 shows no similarity to PPAR depletion in its effect on
gene expression (Fig. 6). Likewise, a closer analysis of genes
highly expressed in the adipocyte reveals similar changes in
gene expression due to PPAR and SCD2 depletion but not
SCD1 depletion (supplemental Table 1). In these experi-
ments, PPAR depletion by siRNA was only about 50% (data
not shown). Therefore, these results demonstrate the pow-
erful requirement of PPAR for optimal adipocyte-specific
gene expression, as previously published (7). Furthermore,
these results illustrate the distinct roles that the highly sim-
ilar desaturases SCD1 and SCD2 fulfill in the fully differen-
tiated adipocyte.
SCD2 Is Required for Optimal Protein Synthesis in 3T3-L1
Adipocytes—The reduction in PPAR protein but not
mRNA expression in response to SCD2 depletion in fully
differentiated adipocytes may be due to a decrease in its
synthesis or an increase in its degradation. Cultured adipo-
cytes were, therefore, treated with cycloheximide to inhibit
protein synthesis and determine whether PPAR degrada-
tion is increased upon loss of SCD2. Using this standard
method to determine the protein degradation rate in the
presence of cycloheximide, PPAR protein levels were
assessed in adipocytes that were electroporated with scram-
bled siRNA or siRNA directed against SCD2. As seen in Fig.
7, the rate of loss of PPAR protein is rapid upon this treat-
ment, exhibiting a short half-life of 1.5 h similar to what
has been previously reported (30). However, the rate of
PPAR degradation is similar between control and SCD2-
depleted cells, indicating no change in response to loss of
SCD2. Therefore, these results confirm rapid turnover of
PPAR protein in adipocytes and indicate that SCD2 does
not promote PPAR degradation.
The results in Fig. 7 indicate that the decrease in PPAR
protein levels in response to the loss of SCD2 in fully differ-
entiated adipocytes is due to decreased synthesis of PPAR
protein. To determine whether SCD2 is required for PPAR
protein synthesis, newly synthesized protein was labeled
with [35S]methionine/cysteine, and PPAR protein was
immunoprecipitated from control and SCD2-depleted cells.
The radioactive signal generated from the immunoprecipi-
tated protein indicates protein that has been newly synthe-
FIGURE 4. The treatment of cultured 3T3-L1 cells with siRNA does not
induce toxicity. A, confluent 3T3-L1 fibroblasts were transfected with PBS
or scrambled nucleotide as controls or SMART-pool siRNA against PPAR,
FAS, SCD1, or SCD2 transcript and differentiated as described. Toxicity was
then determined using the colorimetric MTS cell proliferation assay (Pro-
mega). B, seven days post-differentiation, adipocytes were electroporated
with PBS or scrambled nucleotide as controls or siRNA against PPAR, FAS,
SCD1, or SCD2 transcript. After 72 h, the cells were labeled for apoptosis
using the TdT-mediated dUTP nick-end labeling (TUNEL) assay kit (Pro-
mega), and positively labeled cells were determined by FACS analysis.
DNase-treated cells acted as the positive control.
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sized, whereas the Western blot of the immunoprecipitated
protein shows the total amount of protein present. As seen in
Fig. 8, newly synthesized PPAR1 and PPAR2 are reduced
by 50% in the SCD2 depleted cells, which is similar to the
decrease in total protein levels (Figs. 8 and 5B). Therefore,
because PPAR degradation is not altered (Fig. 7), the
decrease in newly synthesized protein appears to be due to a
decrease in protein synthesis.
A common method to monitor the translational efficiency
of a particular mRNA is by polysome profile analysis. This
methodology separates monosomes from polysomes using a
sucrose density gradient, which is then fractionated to gen-
erate an absorbance profile, indicating which fractions con-
tain monosomes and polysomes. Subsequently, mRNA is
isolated from each fraction to determine the degree to which
a particular mRNA associates with monosomes or poly-
somes. To verify that translation of PPAR is indeed
decreased in response to SCD2 depletion, polysome profile
analysis was performed, and the distribution of PPAR
mRNA with monosomes and polysomes was determined.
The UV absorbance at A254 reveals a decrease in the absorb-
ance in the heavy polysome fractions and an increase in
absorbance in the light polysome and 80 S monosome frac-
tions in cells depleted of SCD2, suggesting that less ribo-
somes are associated with mRNA, and there is a global
reduction in translation. Real time PCR analysis also reveals
that the PPAR mRNA shifts toward the lighter polysome
and monosome fractions, confirming that PPAR is less effi-
ciently translated in the absence of SCD2 (Fig. 8). Therefore,
the decrease in PPAR protein expression is due to a
FIGURE 5. SCD2 is required for PPARprotein, but notmRNAexpression, aswell as the expression of the PPAR-regulatedgenes, phosphoenolpyru-
vate carboxykinase, and ACC in fully differentiated 3T3-L1 adipocytes. Seven days post-differentiation, adipocytes were electroporated with PBS or
scrambled nucleotide as controls or siRNA against PPAR, FAS, SCD1, or SCD2 transcript. After 72 h, RNA was collected to determine the expression of
adipogenic markers by real time PCR using AKT1 as an internal control (A) or protein was collected to determine the expression of PPAR byWestern blot (B).
Changes in protein expressionwere quantified by densitometry; the values for PPAR represent both PPAR1 and PPAR2 isoforms, since both isoforms show
a similar decrease. Thevalues represent the averageof three independent experiments, and theasteriskdenotes ap value0.05.PEPCK, phosphoenolpyruvate
carboxykinase.
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decrease in general protein synthesis and does not specifi-
cally affect PPAR translation.
DISCUSSION
The major finding reported here is the unexpected require-
ment of the fatty acid desaturase isoform SCD2 for both adipo-
genesis and the maintenance of the adipocyte phenotype in
cultured 3T3-L1 cells (Figs. 2, 3, 5, and 6, and supplemental Fig.
1). SCD2 regulates adipogenesis at least in part by controlling
the transcription of the nuclear receptor PPAR (Fig. 2A and
supplemental Fig. 1), whereas in fully differentiated adipocytes
SCD2 is required for optimal protein synthesis, including
PPAR translation (Figs. 7–9). Thus, in 3T3-L1 preadipocytes
and adipocytes, PPAR protein levels are remarkably depend-
ent on the expression levels of SCD2. Interestingly, the inhibi-
tion of adipogenesis by SCD2 depletion was not restored by the
addition of the PPAR-specific ligand, rosiglitazone (Figs. 2 and
3 and supplemental Fig. 1). Therefore, SCD2 does not appear to
be regulating the production of a PPAR ligand. Rather, these
data indicate that in preadipocytes one or more unsaturated
fatty acids generated by the SCD2 enzyme or a protein-protein
interaction dependent on SCD2 is necessary for the normal
functioning of the transcriptionalmachinery that drives PPAR
expression and also to maintain protein synthesis rates in
mature adipocytes.
The surprisingly powerful effects of depleting SCD2 in cul-
tured adipocytes suggest a special role for this enzyme in adi-
pocyte function. We tested the effects of depleting 24 enzymes
that catalyze reactions in fatty acid metabolism in our siRNA-
based screen, but only FAS and SCD2 were found to be neces-
sary for adipogenesis (Figs. 2 and 3 and supplemental Fig. 1).
Mice express 4 isoforms of SCD (SCD1–4), which exhibit
80% sequence similarity, whereas humans have two isoforms
(SCD1 and SCD5) that are 60% similar in sequence (31–33).
However, all fourmouse SCD isoforms are nearly 80% similar to
human SCD1 (31, 32, 34, 35). Mouse SCD1 is the best charac-
terized SCD isoform and is expressed in adipose tissue, liver,
FIGURE 6.Depletion of SCD2, but not SCD1, attenuates the expression of
PPAR-regulated genes. Heat map showing the comparison of genes that
change in expressionwith PPAR, SCD2, or SCD1 depletion. Seven days post-
differentiation, adipocyteswere transfectedwith siRNAagainst PPAR, SCD2,
SCD1, or scramble nucleotide control, and RNA was collected after 72 h to
perform Affymetrix GeneChip analysis. The first column is a comparison of
scrambled nucleotide versus PPAR depletion; the second column is a com-
parison of scrambled nucleotide versus SCD2 depletion; the third column is a
comparison of scrambled nucleotide versus SCD1 depletion. Green bars rep-
resent genes that are significantly up-regulated, and red bars represent genes
that are down-regulated (p 0.05).
FIGURE 7. SCD2 depletion does not enhance degradation of PPAR. Seven
days post-differentiation, adipocytes were electroporated as described, and
after 24 h of siRNA transfection, cells were treated with 5 M cycloheximide.
Protein was collected at the indicated time points and analyzed by Western
blot. Shown is a representative blot. Proteins were quantified by densitome-
try, and the 0.5–3-h time points were normalized to the time 0 time point for
each condition to calculate the -fold change in time for protein turnover. The
graph illustrates the average of six independent experiments.
FIGURE 8. SCD2 depletion inhibits the synthesis of PPAR protein. Seven
days post-differentiation adipocytes were electroporated as described, and
72 h after siRNA transfection, cells were metabolically labeled with [35S]Met/
Cys andwashed several times, and proteinwas collected for PPAR immuno-
precipitation andWestern blot. The radioactive signal was visualized using a
PhosphorImager (Molecular Dynamics) and quantified by densitometry.
Shown is a representative immunoprecipitation (IP) of PPAR labeled with
[35S]Met/Cys or anti-PPAR antibody. The graph illustrates the average of
three experiments, and the asterisk denotes a p value0.01.
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muscle, and sebaceous glands, SCD2 is expressed ubiquitously,
SCD3 is expressed in the harderian gland and in sebocytes in
the skin, and SCD4 is expressed in the heart (31). The reason for
multiple highly homologous isoforms in the mouse has
remained unclear, especially since SCD1 and SCD2 apparently
utilize the same substrates with the same efficiency (29). One
possible explanation for the redundancy in SCD isoforms is the
need for differential expression in various tissues during spe-
cific stages of development (31). However, depletion of SCD1 in
fully differentiated cells did not have a major impact on adipo-
cyte-specific gene expression despite the higher expression of
SCD1 versus SCD2 (supplemental Fig. 2C). Therefore, despite
the predicted similarity in substrate usage and common cellular
localizations of the enzymes, SCD1 and SCD2 appear to have
disparate cellular functions in 3T3-L1 adipocytes (29, 31, 34,
35). Interestingly, Affymetrix Gene Chip analysis reveals that
whenmice are put on a high fat diet, SCD2 expression increases
44-fold, whereas SCD1 expression shows little change (Table
1). These data suggest that SCD2may also have a specific role in
promoting adipogenesis in vivo since its expression increases
during a time of increased adipogenesis (36) despite the already
high expression of SCD1 (34, 37).
It should be noted that the requirement for a 9-desaturase
during adipogenesis is somewhat surprising since Gomez et al.
(38) showed that adipogenesis of 3T3-L1 cells is not affected
when induced in the presence of the SCD chemical inhibitor,
sterculic acid. Perhaps this discrepancy can be explained by a
selectivity of the inhibitor for the highly homologous protein,
SCD1, thereby preserving SCD2 activity and adipogenesis. This
would be consistent with our results showing that the depletion
of SCD1 did not attenuate adipogenesis. Nevertheless, our
studies presented here are not the first evidence suggesting sep-
arate cellular functions of the
enzymes, since SCD1 deficiency
leads to skin abnormalities despite
SCD2 expression in the skin (32).
PPAR protein expression was
found to be dramatically reduced
uponSCD2depletion inmature adi-
pocytes (Figs. 3A and 5B), which
explains why there is a decrease in
the expression of many PPAR-reg-
ulated genes (Fig. 5A). Furthermore,
the reduction in PPAR protein
expression is due to a decrease in
general protein synthesis and not
degradation, since the turnover of
PPAR protein when protein syn-
thesis is inhibited by cycloheximide
is unaffected by the depletion of
SCD2 (Fig. 7). Consistent with this
interpretation, there is a decrease in
newly synthesized PPAR protein
as determined by [35S]methionine/
cysteine labeling (Fig. 8) and in the
association of actively translating
ribosomes with mRNA, including
PPARmRNA (Fig. 9).
Because SCD2 is required for general protein synthesis,
PPAR is not the only protein that is reduced in expression
upon SCD2 depletion. In fact, examination of the total lysate
from cells labeled with [35S]methionine/cysteine shows a sig-
nificant 15% decrease in newly synthesized protein fromSCD2-
depleted cells (data not shown). Unlike PPAR, however, many
proteins decrease in expression on the transcript level; con-
versely,many transcripts also increase in expressionwith SCD2
depletion (Fig. 6), which taken together makes it difficult to
determine the effect of SCD2 on total protein synthesis. SCD2
depletion does result in the post-transcriptional decrease in
expression of proteins other than PPAR, such as AKT1 and 
catenin. The decreased expression of these proteins also
appears to be due to a decrease in translational efficiency since
the association of AKT1 and  cateninmRNA shifts from poly-
somes to monosomes (data not shown). However, we have not
verified that the synthesis of these proteins is decreased using
[35S]methionine/cysteine metabolic labeling or determined if
the degradation rate of these proteins increases with SCD2
depletion; therefore, we cannot conclude that the decrease in
their expression is due to a decrease in translation.
Altogether, our data indicate that unsaturated fatty acids
may regulate a pathway to enhance the machinery of protein
translation in adipocytes. Because oleate is amajor unsaturated
fatty acid product of SCD2, we tested whether exogenous addi-
tion of oleate would restore the decrease in PPAR protein
levels with SCD2depletion (29, 31). However, even the addition
of oleate at a concentration as high as 1 mM did not restore
PPAR levels (data not shown). Therefore, perhaps SCD2 is
required to produce an unsaturated fatty acid other than oleate,
or is required for the proper shuttling of an unsaturated fatty
acid, as seen with linoleate in the SCD2 knock-out mouse (31),
FIGURE9.SCD2depletiondecreasespolysomeassociationwithmRNAinculturedadipocytes.Sevendays
post-differentiation, adipocytes were electroporated as described, and after 24 h of siRNA transfection, cyto-
plasmic extracts were prepared and fractionated on a 10–50% sucrose gradient. The absorbance of each
fractionwasdetermined atA254, and total RNAwas extracted from fractions 2–13. PPARmRNAwasquantified
fromequal volumesof the fractions using real timePCRandexpressed as apercentageof themaximumPPAR
mRNA in each sample. The data shown represents one of four experiments with similar results.
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or is necessary for a protein-protein interaction that regulates
translation.
To our knowledge the only previously published evidence
of regulation by unsaturated fatty acids of protein synthesis
is by arachidonic acid or eicosapentaenoic acid. Arachidonic
acid has been shown to both activate and inhibit protein
translation in diverse cell systems, whereas eicosapentaenoic
acid has been shown to inhibit translation initiation by
inducing eIF2 phosphorylation (39–41). Therefore, we
examined eIF2 phosphorylation in response to depletion of
SCD2 but did not find a difference between SCD2-depleted
and control adipocytes (data not shown). Protein synthesis
can also be controlled through the protein kinases AMP-
activated protein kinase and mTOR (42). An increase in
AMP-activated protein kinase activity could lead to
decreased peptide elongation through activation of eEF2
kinase, which then phosphorylates and inhibits eEF2, a fac-
tor that promotes protein chain elongation. Interestingly,
this pathway may be regulated by unsaturated fatty acids,
since SCD1 deficiency in mice leads to increased AMP-acti-
vated protein kinase activity in the liver (43). In SCD2-de-
pleted adipocytes, we did find an approximate 80% increase
in AMP-activated protein kinase phosphorylation and a
small 20% increase in eEF2 phosphorylation compared with
control cells (data not shown). However, these increases in
AMP-activated protein kinase and eEF2 phosphorylation
associated with SCD2 depletion do not appear tomediate the
decrease we observe in protein synthesis, since eliminating
the increase in phosphorylation of eEF2 by the dual deple-
tion of eEF2 kinase and SCD2 did not restore PPAR protein
levels (data not shown). It is reported that mTOR positively
regulates protein synthesis by phosphorylating and activat-
ing RS6K and 4EBP1 (44, 45). Although SCD2 depletion
causes a reduction in RS6K and 4EBP1 protein levels, it does
not reduce the phosphorylation of these proteins, suggesting
the mTOR pathway is not affected (data not shown). Con-
sistent with these results, inhibition of mTOR with rapamy-
cin also decreases RS6K1 and RS6K2 activity but does not
affect PPAR levels (44, 46, 47). Therefore, it remains
unclear how SCD2 regulates mRNA association with poly-
somes, and this is an important question for future studies to
address.
It will also be interesting in future studies to test whether
SCD2 plays a unique role in modulating glucose homeostasis
in mice.White adipose tissue is a key regulator of whole body
metabolism through its ability to control glucose disposal
and insulin sensitivity in peripheral tissues (1, 17). This reg-
ulation appears to be mediated by two main mechanisms (1,
17, 48), 1) storing excess fatty acids in the form of triglycer-
ide to prevent lipotoxicity in peripheral tissues and 2) secret-
ing insulin-sensitizing factors, such as adiponectin. PPAR
plays a central role in both of these processes by promoting
expression of genes involved in fatty acid esterification to
triglyceride (48) and the expression of adiponectin (48, 49).
SCD2 may have profound influence on these processes
through its regulation of PPAR and adipogenesis. Unfortu-
nately, SCD2/mice do not survive and can not be studied
in this regard. Thus, these important questions regarding the
physiological role of SCD2 in whole body metabolism must
await the generation of mouse models with tissue-specific
depletion of this enzyme.
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